Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Chardan Capital restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. ARWR has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an […]
More Stories
Entrepreneur Support and Blockchain: New Tools for Transparency and Trust
Startups do not fail only from a lack of ideas. Many struggle when trust breaks down, records are hard to...
DOJ Sues Connecticut, City of New Haven Over Sanctuary Policies
By Jackson Richman The U.S. Department of Justice (DOJ) sued Connecticut and the City of New Haven on April 13...
Israel–Lebanon Talks Conclude With Signs of Progress But No Ceasefire Deal
By Ryan Morgan U.S. Secretary of State Marco Rubio hosted the Israeli and Lebanese ambassadors to the United States for...
DEI Practices Reduce Productivity, Cost $94 Billion Annually: White House Economic Report
By Travis Gillmore WASHINGTON—Diversity, equity, and inclusion practices negatively impacted the U.S. economy, according to the 2026 White House Economic...
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...